AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.


Angiopoietin-2 predicts the efficacy of angiogenesis inhibitors in colorectal cancer therapy.
Technology Benefits
Ang-2 level as predictive biomarker for angiognese-targeted therapeutical approaches of CRC.
Low pretherapeutic serum Ang-2 levels are associated with: reduced risk of death, increased progression-free survival.
Technology Application
Cancer Therapy- Strong diagnostic potential of the predictive biomarker has been demonstrated in pretherapeutic blood samples from colorectal cancer patients vs. healthy controls
Detailed Technology Description
A novel predictive biomarker to help identify the patient population with the most favorable clinical outcome to angiogenesis-targeted treatment in mCRC patients.Experiments revealed that patients with low pretherapeutic Ang-2 serum levels receiving a bevacizumab-containing treatment were associated with a better response rate compared to patients with high pretherapeutic Ang-2 levels
Type of Cooperation
Application Date
06/09/2010 00:00:00
Application No.
EP20100757580 20100906
- international:
- cooperative:
G01N33/57419; G01N2333/515; G01N2800/52; G01N2800/56
Patent application
ID No.

For more information, please click Here
Mobile Device